Trials of a new drug for obesity and type 2 diabetes have seen patients lose 15pc of their body weight and return their blood ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

Projections show half of ten and 11-year-olds could be overweight or obese in some areas, with experts calling for urgent ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Ecnoglutide is a GLP-1 receptor agonist, part of a growing class of drugs that help control blood sugar and reduce hunger.

A new report reveals a stark rise in childhood obesity rates across England, with projections showing that more than 40% of ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

Obesity caused by a high-fat Western diet damages the pancreas, affecting insulin production and blood sugar control even ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Head of the Metabolic Neuroscience Laboratory, investigates the brain ‘goo’ behind obesity and Type-2 diabetes - and how we ...